Global Biomarker Partnering Terms and Agreements 2010-2016

Mar 17, 2016, 13:10 ET from Research and Markets

DUBLIN, March 17, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9xq3lz/global_biomarker) has announced the addition of the "Global Biomarker Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.

The Global Biomarker Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors.

A biomarker, or biological marker, is an indicator of a biological state, or disease state as in medicinal use. It is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In Global Biomarker Partnering 2010-2016: Deal trends, players, financials and forecasts, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biomarker dealmaking

Chapter 3 - Leading Biomarker deals

Chapter 4 - Most active Biomarker dealmakers

Chapter 5 - Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

Chapter 7 - Partnering resource center

For more information visit http://www.researchandmarkets.com/research/9xq3lz/global_biomarker

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com